{"changeSha256":"3879421e302ca91fc8f6b3ec1e59c13b534ab2f2e3a9a01cc7e7c9845e924c06","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Tymlos for osteoporosis","before":"U.S. label record","field":"Status"},{"after":"A PTHrP analogue approved by FDA as Tymlos for postmenopausal women with osteoporosis at high risk of fracture and to increase bone density in men with osteoporosis.","before":"A parathyroid hormone-related peptide analogue. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that abaloparatide caused osteosarcoma in rats and that it is unknown whether it does so in humans.","before":"The cited DailyMed label identifies Abaloparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19, fda-drugs-nda208743-2017-04-28-566de3ccde8d","before":"dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda208743-2017-04-28-566de3ccde8d]","before":"U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19]","field":"Named organizations"},{"after":"name: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; aliases: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; category: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; status: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19, fda-drugs-nda208743-2017-04-28-566de3ccde8d; summary: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19, fda-drugs-nda208743-2017-04-28-566de3ccde8d; evidenceNote: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19","before":"name: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; aliases: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; category: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; status: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; summary: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; evidenceNote: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/abaloparatide/versions/4/","version":4},"id":"profile:abaloparatide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the Tymlos label, and added the Drugs@FDA approval record.","peptideSlugs":["abaloparatide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/abaloparatide/v3.json","sha256":"325edcad5ac1152f63a92ebeb9c5c2887e48a451132ef4f8245ccf028498ce91"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/abaloparatide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"TYMLOS (abaloparatide) injection, solution · SPL version 19 · published 2026-08-17","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=712143d9-e21e-4013-bb3b-3426a21060a8&version=19","verifiedAt":"2026-09-15"},{"id":"fda-drugs-nda208743-2017-04-28-566de3ccde8d","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA208743 · original submission status AP · 2017-04-28 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208743%22&limit=1","verifiedAt":"2026-08-14"}],"subject":{"slug":"abaloparatide","type":"profile"}}
